Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Surgeon General

This article was originally published in The Tan Sheet

Executive Summary

"No conclusions about the role, if any, of complementary and alternative treatments in mental health or illness can be accepted with certainty, as very few claims or studies meet acceptable scientific standards," a report on mental health from the Surgeon General states. Released Dec. 13 at a press conference featuring Surgeon General David Satcher, MD/PhD, HHS Secretary Donna Shalala and Tipper Gore, the report says, "In many cases, preparations are not standardized and consist of a variable mixture of substances, any of which may be the active ingredient(s). Purity, bioavailability, amount and timing of doses...cannot be taken for granted with natural products." However, the report notes several government studies that should help shed light on such products' efficacy are scheduled to begin shortly. A trial of St. John's wort funded by the National Institutes of Health already is underway (1"The Tan Sheet" June 15, 1998, p. 18)

You may also be interested in...



NIMH St. John's wort trial, using Lichtwer Pharma product, to begin in October.

NIMH ST. JOHN's WORT TRIAL TO USE LICHTWER BOTANICAL in the medication administered to participants randomized to receive active tablets. Patient enrollment is scheduled to begin in October. The eight-week, three-arm clinical trial of Hypericum perforatum first will compare the safety and efficacy of the herbal ingredient against placebo in treating depression ("The Tan Sheet" June 23, 1997, p. 18). Pfizer's Zoloft (sertraline), an Rx selective serotonin re-uptake inhibitor, will be used in the third arm of the trial to document the study's sensitivity, although the trial will not have sufficient power to compare sertraline and St. John's wort.

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Topics

UsernamePublicRestriction

Register

PS090706

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel